Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer

医学 叶黄素 吉西他滨 伊立替康 内科学 胰腺癌 佐剂 肿瘤科 辅助治疗 癌症 结直肠癌
作者
Thierry Conroy,Florence Castan,Anthony Lopez,Anthony Turpin,Méher Ben Abdelghani,Alice C. Wei,Emmanuel Mitry,James Biagi,Ludovic Evesque,Pascal Artru,Thierry Lecomte,Éric Assenat,Lucile Bauguion,Marc Ychou,Olivier Bouché,Laure Monard,Aurélien Lambert,Pascal Hammel,Éric François,Jean‐François Ramée
出处
期刊:JAMA Oncology [American Medical Association]
卷期号:8 (11): 1571-1571 被引量:196
标识
DOI:10.1001/jamaoncol.2022.3829
摘要

Early results at 3 years from the PRODIGE 24/Canadian Cancer Trials Group PA6 randomized clinical trial showed survival benefits with adjuvant treatment with modified FOLFIRINOX vs gemcitabine in patients with resected pancreatic ductal adenocarcinoma; mature data are now available.To report 5-year outcomes and explore prognostic factors for overall survival.This open-label, phase 3 randomized clinical trial was conducted at 77 hospitals in France and Canada and included patients aged 18 to 79 years with histologically confirmed pancreatic ductal adenocarcinoma who had undergone complete macroscopic (R0/R1) resection within 3 to 12 weeks before randomization. Patients were included from April 16, 2012, through October 3, 2016. The cutoff date for this analysis was June 28, 2021.A total of 493 patients were randomized (1:1) to receive treatment with modified FOLFIRINOX (oxaliplatin, 85 mg/m2 of body surface area; irinotecan, 150-180 mg/m2; leucovorin, 400 mg/m2; and fluorouracil, 2400 mg/m2, every 2 weeks) or gemcitabine (1000 mg/m2, days 1, 8, and 15, every 4 weeks) as adjuvant therapy for 24 weeks.Primary end point was disease-free survival. Secondary end points included overall survival, metastasis-free survival, and cancer-specific survival. Prognostic factors for overall survival were determined.Of the 493 patients, 216 (43.8%) were women, and the mean (SD) age was 62.0 (8.9) years. At a median of 69.7 months' follow-up, 367 disease-free survival events were observed. In patients receiving chemotherapy with modified FOLFIRINOX vs gemcitabine, median disease-free survival was 21.4 months (95% CI, 17.5-26.7) vs 12.8 months (95% CI, 11.6-15.2) (hazard ratio [HR], 0.66; 95% CI, 0.54-0.82; P < .001) and 5-year disease-free survival was 26.1% vs 19.0%; median overall survival was 53.5 months (95% CI, 43.5-58.4) vs 35.5 months (95% CI, 30.1-40.3) (HR, 0.68; 95% CI, 0.54-0.85; P = .001), and 5-year overall survival was 43.2% vs 31.4%; median metastasis-free survival was 29.4 months (95% CI, 21.4-40.1) vs 17.7 months (95% CI, 14.0-21.2) (HR, 0.64; 95% CI, 0.52-0.80; P < .001); and median cancer-specific survival was 54.7 months (95% CI, 45.8-68.4) vs 36.3 months (95% CI, 30.5-43.9) (HR, 0.65; 95% CI, 0.51-0.82; P < .001). Multivariable analysis identified modified FOLFIRINOX, age, tumor grade, tumor staging, and larger-volume center as significant favorable prognostic factors for overall survival. Shorter relapse delay was an adverse prognostic factor.The final 5-year results from the PRODIGE 24/Canadian Cancer Trials Group PA6 randomized clinical trial indicate that adjuvant treatment with modified FOLFIRINOX yields significantly longer survival than gemcitabine in patients with resected pancreatic ductal adenocarcinoma.EudraCT: 2011-002026-52; ClinicalTrials.gov Identifier: NCT01526135.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Star完成签到,获得积分10
1秒前
1秒前
柔弱的不二完成签到,获得积分10
2秒前
无心的枫完成签到,获得积分10
4秒前
djdh完成签到 ,获得积分10
4秒前
肖果完成签到 ,获得积分10
7秒前
哭泣笑柳发布了新的文献求助10
8秒前
CipherSage应助长安采纳,获得10
9秒前
飒飒完成签到,获得积分10
10秒前
RONG完成签到 ,获得积分10
10秒前
落落完成签到,获得积分10
11秒前
Yan完成签到 ,获得积分10
12秒前
12秒前
谨慎的凝丝完成签到 ,获得积分10
13秒前
雨洋完成签到,获得积分10
14秒前
chi完成签到 ,获得积分10
15秒前
还单身的湘完成签到,获得积分10
17秒前
fyjlfy完成签到 ,获得积分10
17秒前
深情安青应助Nayvue采纳,获得10
18秒前
研友_Y59785完成签到,获得积分0
18秒前
Xiaoxiao发布了新的文献求助10
19秒前
初初见你完成签到,获得积分10
26秒前
29秒前
思源应助淡淡月饼采纳,获得20
29秒前
dd完成签到 ,获得积分10
30秒前
Nayvue发布了新的文献求助10
34秒前
未来的幻想完成签到,获得积分10
36秒前
Kvolu29完成签到,获得积分10
37秒前
长理物电强完成签到,获得积分10
38秒前
若安在完成签到,获得积分10
39秒前
完美世界应助潘特采纳,获得10
40秒前
拼搏问薇完成签到 ,获得积分10
40秒前
单薄乐珍完成签到 ,获得积分0
43秒前
张静枝完成签到 ,获得积分10
43秒前
六步郎完成签到,获得积分10
43秒前
啊怙纲完成签到 ,获得积分10
45秒前
量子星尘发布了新的文献求助10
47秒前
scott_zip完成签到 ,获得积分10
48秒前
gxl完成签到,获得积分0
52秒前
xxx完成签到 ,获得积分10
55秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038184
求助须知:如何正确求助?哪些是违规求助? 3575908
关于积分的说明 11373872
捐赠科研通 3305715
什么是DOI,文献DOI怎么找? 1819255
邀请新用户注册赠送积分活动 892662
科研通“疑难数据库(出版商)”最低求助积分说明 815022